By Debdeep Gupta | 17 Dec, 2024
Brokerage Radar: Morgan Stanley 'Underweight' on Wipro, JM Financial initiates coverage on Piramal Pharma with 'Buy'
Morgan Stanley On WiproUnderweight Call, Target At `250/ShAfter Capco (2021) & Rizing (2022) Acquisition, See Applied Value Tech Acqn Being Relatively SmallSee The Acqn Supporting More Of Capability Boost & Adding Some Marquee Clients To PortfolioGiven Small Scale, See Acquisition Having A Limited Impact On Financials In FY25/FY26CLSA On ITTCS, Infosys & Wipro, In Their Quarterly Preview, Showed C...
Live Comments